Appendix 3Y

Rule 3.19A.2

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SomnoMed Limited
ABN	35 003 255 221

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lee Ausburn
Date of last notice	22nd March 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Leedoc Pty Limited a company associated with Ms Ausburn (as to 57,177 shares)	
Date of change	22 nd April 2020	
No. of securities held prior to change	137,096 ordinary shares	
Class	Ordinary Shares	
Number acquired	20,000 shares	
Number disposed	-	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.80 per share	
No. of securities held after change	157,096 ordinary shares	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Entitlement Offer announced on 25 March 2020	

⁺ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

N/A
N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No - Pro-rata entitlement offer
above traded during a ⁺ closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.